The MIND Prize funds bold, interdisciplinary research to transform understanding and treatment of neurodegenerative diseases like Alzheimer’s, supporting innovative early-to-mid-career scientists.
Funder: Pershing Square Philanthropies
Due Dates (Anticipated): September 2026 (Letter of Intent, projected)
Funding Amounts: $750,000 total ($250,000/year for 3 years, includes up to 10% indirect costs)
Summary: Supports early-to-mid-career investigators for high-risk, innovative research in neurodegenerative diseases, with a focus on radically advancing brain science and therapeutics.
Key Information: Forecasted opportunity—dates and details are projected; check the program page for updates.
The MIND Prize, offered by Pershing Square Philanthropies, aims to empower early-to-mid-career investigators who are pursuing radically innovative and interdisciplinary research in neurodegenerative diseases (NDDs) such as Alzheimer’s Disease and Dementia. The initiative seeks to revolutionize the prediction, prevention, and treatment of NDDs by advancing fundamental understanding of the brain and cognition. The prize encourages high-risk, high-reward projects that may be too speculative for traditional funding sources, spanning areas such as neurobiology, brain imaging, machine learning, drug delivery, and synthetic biology. Awardees benefit from facilitated networking, mentorship, and participation in a unique community of pioneering researchers.